Reckitt Benckiser said it was not aware of any evidence that ibuprofen adversely impacts patients suffering from COVID-19, as reported by London South East.
The company produces the nonsteroidal anti-inflammatory drug Nurofen, which has ibuprofen as an active ingredient, and is indicated to treat pain and inflammation and to reduce fever.
The statement follows recent remarks by France's health minister, who said "the taking of anti-inflammatories [ibuprofen, cortisone…] could be a factor in aggravating the infection."
Olivier Véran also advised that "in case of fever, take paracetamol. If you are already taking anti-inflammatory drugs, ask your doctor's advice."
Reckitt Benckiser said it "has neither received new safety information nor been involved in the evaluation of any adverse events regarding the use of ibuprofen in COVID-19."
It added that "appropriate use of ibuprofen and paracetamol is still currently being recommended by most European health authorities as part of the symptomatic treatment of COVID-19."
To read more NewsPoints articles, click here.